EGFR and metastatic colorectal cancer: The US Food and Drug Administration has approved targeted therapies as first-line treatment for patients with metastatic colorectal cancers in combination with 5-FU-based chemotherapy [47], such as bevacizumab (a monoclonal antibody against VEGF) and cetuximab (a monoclonal antibody against EGFR), but limited data have discouraged their use during pregnancy.